glp-1 medication risks compounding pharmacies Overdose increase as demand for injectable weight-loss drugs on the rise, research finds Can You Trust Compounded GLP-1s?
Description
10.1111/j.1464-5491.2010.03010.x 70
Conflict of interest JR-F declares that he has received honoraria for lectures for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Novartis, Abbvie, Merck, and Bayer
however, close monitoring for gastrointestinal adverse events is warranted in cirrhotic patients, who may have reduced tolerance
The improvement in peak shape and increased sensitivity with the use of the low adsorption LC column hardware was striking
